Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia-Reference-Cited by-同舟云学术

Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia

Published:2020-06-19 Issue:10 Volume:61 Page:2399-2408
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Madamsetty Vijay Sagar¹^ORCID,Paulus Aneel²,Akhtar Sharoon²,Manna Alak²,Rachamalla Harikrishna Reddy³⁴,Banerjee RajKumar³⁴,Mukhopadhyay Debabrata¹,Chanan-Khan Asher¹⁵⁶

Affiliation:

1. Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Jacksonville, FL, USA;

2. Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA;

3. Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, India;

4. Academy of Scientific and Innovative Research (AcSIR, CSIR - Human Resource Development Centre, (CSIR-HRDC) Campus, Ghaziabad, India;

5. Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA;

6. Mayo Clinic Cancer Center at St. Vincent's Medical Center Riverside, Jacksonville, FL, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1775204

Reference35 articles.

1. Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility

2. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

3. Waldenström’s Macroglobulinemia: Clinical Features, Complications, and Management

4. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells

5. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway;Cancer Research;2023-05-19

2. Encapsulation for general cancer treatment;Principles of Biomaterials Encapsulation : Volume Two;2023

3. Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems;ACS Biomaterials Science & Engineering;2022-04-19

4. Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations;Biomolecules;2021-12-30

5. Targeting steroid hormone receptors for anti‐cancer therapy—A review on small molecules and nanotherapeutic approaches;WIREs Nanomedicine and Nanobiotechnology;2021-09-19